By Joshua Kirby

Lonza Group AG on Thursday provided guidance for 2023, saying it expects double-digit growth in sales and higher margins driven by growth in the biologics, small molecules and cell and gene therapy divisions.

The Swiss chemicals-and-biotechnology group said it sees sales growth in the double digits in 2023, while its core earnings before interest, taxes, depreciation and amortization margin should be around 33%-35%. Return on invested capital should also be in the double digits in 2023, Lonza said.

Capital expenditure in 2021 and 2022 will likely remain at the same level as in 2019, the company added.

Write to Joshua Kirby at joshua.kirby@dowjones.com

(END) Dow Jones Newswires

10-15-20 0145ET